Nanoparticle Delivery to Tumours: From EPR and ATR Mechanisms to Clinical Impact.
Where this comes from
- Record sourced from PubMed, PMID 39376248.
- Also identified by DOI 10.1038/s44222-024-00203-3 and PMC identifier 7616668.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New insights into active versus passive nanoparticle tumour entry and exit mechanisms are enriching the understanding of tumour-targeted drug delivery. Here, we align the principles of the enhanced permeability and retention (EPR) and active transport and retention (ATR), and outline how their mechanistic features may be employed to improve the performance and clinical impact of cancer nanomedicines.